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The primary vascular dysregulation syndrome:
implications for eye diseases
Josef Flammer1*, Katarzyna Konieczka1 and Andreas J Flammer2
Abstract
Vascular dysregulation refers to the regulation of blood flow that is not adapted to the needs of the respective
tissue. We distinguish primary vascular dysregulation (PVD, formerly called vasospastic syndrome) and secondary
vascular dysregulation (SVD). Subjects with PVD tend to have cold extremities, low blood pressure, reduced feeling
of thirst, altered drug sensitivity, increased pain sensitivity, prolonged sleep onset time, altered gene expression in
the lymphocytes, signs of oxidative stress, slightly increased endothelin-1 plasma level, low body mass index and
often diffuse and fluctuating visual field defects. Coldness, emotional or mechanical stress and starving can provoke
symptoms. Virtually all organs, particularly the eye, can be involved. In subjects with PVD, retinal vessels are stiffer
and more irregular, and both neurovascular coupling and autoregulation capacity are reduced while retinal venous
pressure is often increased. Subjects with PVD have increased risk for normal-tension glaucoma, optic nerve
compartment syndrome, central serous choroidopathy, Susac syndrome, retinal artery and vein occlusions and
anterior ischaemic neuropathy without atherosclerosis. Further characteristics are their weaker blood–brain and
blood-retinal barriers and the higher prevalence of optic disc haemorrhages and activated astrocytes. Subjects with
PVD tend to suffer more often from tinnitus, muscle cramps, migraine with aura and silent myocardial ischaemic
and are at greater risk for altitude sickness. While the main cause of vascular dysregulation is vascular
endotheliopathy, dysfunction of the autonomic nervous system is also involved. In contrast, SVD occurs in the
context of other diseases such as multiple sclerosis, retrobulbar neuritis, rheumatoid arthritis, fibromyalgia and giant
cell arteritis. Taking into consideration the high prevalence of PVD in the population and potentially linked
pathologies, in the current article, the authors provide recommendations on how to effectively promote the field in
order to create innovative diagnostic tools to predict the pathology and develop more efficient treatment
approaches tailored to the person.
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1. Introduction
The amount of blood needed in various organs and tis-
sues varies greatly over time, which is why there is a de-
mand for a sophisticated blood flow (BF) regulation.
This is achieved by adapting perfusion pressure and
local resistance to flow; resistance, thereby, is a function
of the vessel diameter. The term vasospasm denotes an
inappropriate constriction of an artery [1]. If such
spasms occur in several organs simultaneously or se-
quentially, the condition is referred to as vasospastic
syndrome [2]. The term vascular dysregulation, how-
ever, is a broader term that embraces arterial spasms
and also inappropriate constrictions and/or dilatation
of arteries, veins or capillaries, often accompanied by a
barrier dysfunction [3,4]. Vascular dysregulation can lead to
both over and under perfusion of a particular supply terri-
tory. If vascular dysregulation is associated with
symptoms or signs, the term vascular dysregulation
syndrome is used. This syndrome can be primary
(primary vascular dysregulation syndrome, PVD syn-
drome) or secondary to another disease (secondary
vascular dysregulation syndrome, SVD syndrome).
Vascular dysregulation can involve any organ;
however, the eye is particularly often affected. In this
review, we summarise the basic aspects of vascular
dysregulation and focus on its role in the pathogenesis
of eye diseases.
2 Regulation of blood flow
2.1 Function of blood flow
One of the major functions of BF is its transport capability.
It transports not only cells, ions and molecules but,
importantly, also heat. In a nutshell, blood circulation
connects organs, allowing the body to function as an
integrative system.
Adequate and inadequate BF has a huge impact on
human health and disease. The generally best known
causes of disturbed BF are related to the consequences
of advanced atherosclerosis and/or its secondary events
like thrombosis and embolism. The risk factors for
atherosclerosis have been studied extensively. Its medical
and socio-economic impacts are most visible after a
cerebrovascular insult or myocardial infarction. Vascular
dysregulation is another, but far less well known, cause
of a disturbed BF to organs, and its often-neglected role
in the pathogenesis of several diseases will be discussed
in detail in this review.
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2.2 Regulation of blood flow in general
There are two different regulatory components: the
global circulation of the entire body and the distribution
of BF to the individual organs or parts of them.
2.2.1 Global blood circulation
The heart pumps blood into the arteries, building up a
pressure gradient from the arteries over the capillaries to
the veins back to the heart. The global circulation equals
the cardiac output, which is the amount of blood that is
pumped by the heart per unit of time. This cardiac
output is a function of heart rate and stroke volume. It
is constantly adapted to the overall need of the body.
During physical activity, for example, it can be four to
five times larger than when at rest. Cardiac output is
mainly controlled by the autonomic nervous system and
circulating hormones.
Blood pressure results from the relationship between
cardiac output and the overall resistance to flow.
Blood pressure in itself, therefore, does not reflect the
overall BF or the BF to the individual organs. In other
words, a patient with systemic arterial hypertension or
hypotension does not automatically have a higher or a
lower overall perfusion.
2.2.2 Blood supply to individual organs
The demand of BF to different organs or parts of the
organs varies partially independently. The distribution of
cardiac output is therefore regulated by adapting the
relative local resistance.
The BF to a tissue depends on the relationship
between local perfusion pressure and local resistance to
flow. Therefore, perfusion pressure alone is a weak
parameter for the BF of an organ with autoregulation. If,
however, the local regulation of BF in an organ is disturbed
or absent, perfusion pressure becomes the dominant factor.
Vascular resistance is regulated particularly in arteries and,
to some extent, also in capillaries and veins. An increased
resistance in the veins increases venous pressure and
thereby reduces perfusion pressure and also increases
transmural pressure in the capillaries. This leads potentially
to higher extravasation of fluid.
The size of the vessels is regulated by contraction
(vasoconstriction) or relaxation (vasodilatation) of the
smooth muscle cells in arteries and veins and of
pericytes in the capillaries. The smooth muscle cells get
the corresponding information from different sources.
They sense tension (myogenic regulation), and a large
number of factors such as K+, H+ or CO2 originating
from the surrounding tissues influence smooth muscle
cells either directly or indirectly via endothelial cells.
In addition, smooth muscle cells get information from
the autonomic nervous system and from molecules
circulating in the blood.
2.2.3 The role of vascular endothelial cells
The endothelium is a thin layer of cells lining the inner
parts of arteries, capillaries, veins and lymphatic vessels,
thereby forming a structural barrier between the vascular
space and the surrounding tissue. It is a dynamic organ,
important in several housekeeping functions such as
haemostasis, barrier function, immune and inflammatory
responses, angiogenesis and particularly in the regulation
of vascular tone. It has autocrine, paracrine and endocrine
functions (Figure 1). It perceives mechanical information
like sheer stress and traction as well as biochemical infor-
mation, particularly via the circulating molecules [5-7].
Multiple factors, such as cardiovascular risk factors, genetic
factors and inflammation, can influence the endothelium
and predispose a subject to endothelial dysfunction [8]. A
dysfunctional endothelium is involved in the pathogenesis
of various diseases, which are called endotheliopathies [9].
A dysfunction of vascular endothelial cells (VEC) also plays
a role in eye diseases. There is, for example, a relationship
between reduced vascular endothelial progenitor cells and
reduced flow-mediated dilation in glaucoma patients [10].
We also gain insight into the function of VEC from
the analysis on neurovascular coupling in the retina.
Stimulation with a flickering light leads to a quick
dilatation of small vessels and, thereby, to a dilatation
of larger retinal vessels by a mechanism called flow-
mediated vasodilatation. A prerequisite for this dilatation is
a normal VEC function. Interestingly, reduced or even
absent response, as quantified by the retinal vessel analyser,
can be observed in both healthy PVD subjects [11] and in
glaucoma patients progressing despite an intraocular
pressure (IOP) in the normal range [12].
2.3 Regulation of ocular blood flow
2.3.1 Anatomy of ocular blood supply
The eye is supplied by two vascular systems: the
uveal and the retinal vessels. The uveal vascular
system supplies the iris, the ciliary body and the
choroid and also, by diffusion, the outer layers of
the retina, including the photoreceptors. The retinal
vessels supply the inner layers of the retina including
the retinal ganglion cells.
Both the uveal and retinal vessels originate from the
ophthalmic artery, which in turn is a branch of the
internal carotid artery. The central retinal artery
provides blood, and the central retinal vein drains
the retina. The anterior choroid is supplied by the
long ciliary arteries, whereas the posterior choroid is
supplied by the short posterior ciliary arteries. The
entire choroid drains into the vortex veins.
The retinal BF is characterised by a low perfusion rate,
a high vascular resistance and a high oxygen extraction.
By contrast, the choroid shows a high perfusion rate, a
low vascular resistance and a low oxygen extraction.
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The BF in different tissues in the eye is regulated
differently [13]. These regulations will therefore be
discussed separately.
2.3.2 Regulation of retinal blood flow
Retinal vessels are very similar to brain vessels. However,
only the extraocular part but not the intraocular part
has autonomic innervation [14]. Proper retinal function
requires the presence of a blood-retinal barrier. This
physiological barrier regulates the flux of ions, proteins,
hormones and water and also regulates infiltration of
immune competent cells.
Retinal BF depends on the relationship between perfusion
pressure and local resistance. Perfusion pressure is the
difference between retinal arterial and retinal venous
pressure. Under physiological conditions, retinal venous
pressure is often more or less equal to the IOP. There are,
however, a number of conditions in which retinal venous
pressure is distinctly higher than the IOP [15].
Retinal BF, similar to brain BF, is autoregulated.
Autoregulation is the intrinsic capacity to maintain constant
flow despite changes in perfusion pressure. Autoregulation,
however, is effective only within certain limits of perfusion
pressure.
The size of retinal vessels and, thereby, the retinal
circulation are also influenced by retinal activity. This con-
nection is called neurovascular coupling. Neuronal activity
in the central nervous system (including the retina) evokes
localised changes in BF. The magnitude and the spatial lo-
cation of these changes are tightly linked to changes in
neural activity through a complex sequence of coordinated
events involving neurons, glia and the vascular walls. The
neurovascular coupling also provides a basis for functional
imaging. If flickering light hits the retina, blood vessels di-
late within seconds. The direct visual accessibility of fundus
blood vessels allows direct monitoring of this response
in vivo.
2.3.3 Regulation of choroidal blood flow
Choroidal BF regulation is distinctly different from the
regulation of retinal BF [16,17]. The choroidal vessels are
extensively innervated [18,19] (Figure 2). In addition to
Figure 1 VEC receive physical and chemical information, integrate it and release vasoactive substances regulating vascular tone.
(From [5], with permission).
Figure 2 Confocal microscopy of a whole mount from a Rhesus
monkey choroid. After staining of neural structures with a neuronal
marker. Groups of ganglion cells are connected by axon bundles.
Choroidal arteries are densely surrounded by perivascular nerve
fibres. (From [20], with permission).
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providing oxygen and other molecules, choroidal circula-
tion also regulates eye temperature and most likely contrib-
utes to the fine-tuning of accommodation by regulating
choroid thickness. This vascular bed is only partly
autoregulated. The capillaries are fenestrated. Therefore,
there is no or only little oncotic pressure gradient between
intra- and extravascular spaces. The lack of oncotic pres-
sure together with the absence of lymphatic vessels explains
the choroidal effusion if IOP drops below a certain level.
Ciliary BF is similar to choroidal BF. Blood supply to
the ciliary body is a prerequisite for the formation of
aqueous humour [21]. A major drop of ciliary body BF
therefore leads to a reduction of aqueous humour
formation and, thereby, to a reduction of IOP.
2.3.4 Regulation of optic nerve head blood flow
Blood supply to the optic nerve head (ONH) is very
unique by any standard. The superficial layer of the
ONH receives its blood supply via small branches of the
central retinal artery. The prelaminar region (a small
area anterior to the lamina cribrosa), however, is mainly
supplied by branches from the choroidal arteries and
directly from the short posterior ciliary arteries. The
prelaminar area contains no arterioles, but has capillaries
that are exceptionally long. In contrast to the arterial
supply, venous drainage of the ONH is through the
central retinal vein. The autoregulation in this area is
less efficient than in the retina but better than in the
choroid [22,23]. The ONH seems to be the only part of the
central nervous system that has no proper blood–brain
barrier. This is due to a lack of a proper blood–brain
barrier of its capillaries [24] and to the fact that molecules
can diffuse into the ONH from the surrounding choroid
[25]. The diffusing vasoactive substances influence both
size and barrier function of the vessels in the ONH and the
adjacent retina. This is exemplified by endothelin-1 (ET-1)
in Figure 3. Increased plasma concentrations of ET-1 reach
the vascular endothelial cells and exert a more or less neu-
tral effect on the vessel size, as long as the blood–brain
barrier is intact. If, however, the blood–brain barrier
is disrupted, ET-1 gets direct access to the vascular
smooth muscle cells. If the proximate retina is
hypoxic, hypoxia-inducible factor-1α (HIF-1α) is
increased and acts as a transcription factor, stimulating
(among other molecules) the production of vascular
endothelial growth factor (VEGF) or ET-1. This leads to
both vasoconstriction and weakening of the blood–brain
barrier in the corresponding area. Circulating ET-1 can also
Figure 3 Influence of ET-1 on blood vessels in the optic nerve head and adjacent retina. (A) Circulating ET-1 reaches the endothelial cells
(A1) and has a more or less neutral effect. If the blood–brain barrier is disrupted, it reaches directly the vascular smooth muscle cells (A2) and
induces vasoconstriction. (B) Hypoxic retina produces ET-1 diffusing to neighbouring vessels. (C) ET-1 diffuses from fenestrated capillaries into the
optic nerve head and adjacent retina, leading to vasoconstriction and, thereby, also to increased retinal venous pressure. (Modified from [26],
with permission).
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diffuse from the fenestrated choriocapillaries directly into
the ONH and adjacent retina bypassing the blood–brain
barrier. Therefore, both local pathologies and systemic
changes have a potential impact on ONH vessels, both ar-
teries and veins (Figure 3).
3 Vascular dysregulation
The need for BF to different organs varies, and this is
adapted by local vascular regulation. Such an adaption
can be insufficient or improper. A patient with intermittent
claudication, for example, cannot - due to atherosclerosis -
properly increase blood supply to the muscles of the legs
while walking. The adaption of BF, however, can also be
insufficient, despite anatomically normal vessels, due to a
dysfunctional regulation of vascular tone [1,4]. This may be
illustrated by red and white blotches on the face and
neck of certain people when they are stressed. This is
harmless but illustrates the basic characteristics of
vascular dysregulation: the blood supply to a given
organ is, for a period of time, not properly adapted
to the need of this organ. Vascular dysregulation
stands for an inadequate constriction or insufficient
dilatation, as well as excessive dilatation of arteries,
capillaries or veins. Such vascular dysregulation is
often associated with other vascular dysfunctions,
such as weakening of the blood–brain barrier [26] and also
with seemingly independent signs and symptoms [27].
Global vascular dysregulation syndromes can be
divided into primary vascular dysregulation and secondary
vascular dysregulation syndromes. PVD is a predisposition
to respond differently to a variety of stimuli like coldness
or emotional stress. SVD is a dysfunction of anatomically
healthy vessels, induced secondarily by an underlying
disease [28].
3.1 Primary vascular dysregulation
Because PVD is an important risk factor for several eye
diseases [1,3], we will discuss this entity in more detail.
As outlined above, the PVD syndrome is a general
predisposition to respond differently than unaffected
persons do to a variety of stressors and stimuli, such as
coldness, emotional stress and others. The most prominent
aspect is the dysregulation of the vascular tone, giving the
syndrome its name. However, other clinical signs and
symptoms are often associated as well. Due to the
lack of a gold standard for diagnosis and differences
among populations, we do not know the exact prevalence
of PVD. While in Switzerland 31% of women and 7% of
men complain of cold extremities [29], only about
10% of women and 3% of men show the classic
symptoms of PVD [30]. The term PVD should not be
confused with the term posterior vitreous detachment.
3.1.1 Risk factors for PVD
Most of the subjects with PVD indicate that a parent
suffered from the same syndrome. It is therefore likely
an inherited disposition.
The syndrome manifests itself at, or shortly after,
puberty and mitigates or even disappears with older age,
particularly in females after menopause. The prevalence
is much higher in women than in men [29]. Like
migraine [31], PVD symptoms can recur if females take
oestrogen replacement therapy after menopause. Therefore,
oestrogen most likely plays a role as well.
Based on clinical experience, the syndrome occurs
more often in academics than in blue-collar workers and
more in Asians than in Caucasians. Although all these
associations are obvious, the causal relationship is still
unclear. The gender difference may partly be explained
by differences in distribution of adrenergic receptors
[32]. PVD is much more prevalent in slim people
than in obese people [33]. Interestingly, patients with
normal-tension glaucoma (NTG) also tend to be slim
[34], and progression of NTG is often faster in patients
with low body mass index (BMI) [35,36].
3.1.2 Pathomechanisms of PVD
The exact pathogenesis for the development of PVD is
still unclear. On the one hand, the autonomic nervous
system is involved and contributes to the symptoms
[37,38], but on the other hand, the un-innervated retinal
vessels are also involved. Therefore, PVD cannot be
explained by the dysfunction of the autonomic nervous
system only. Importantly, endothelial dysfunction is also
involved; however, it is unclear what mechanism leads to
such a type of endotheliopathy. An imbalance of ET-1
and nitric oxide (NO) production is most likely a major
player and has been observed in glaucoma patients
[39]. The mitochondria are also involved, although it
is difficult to know whether they play a primary role
or if they are involved secondarily [40,41].
3.1.3 Trigger factors for PVD
Subjects with a predisposition for PVD have only minor
symptoms, as long as they are not challenged. A classical
challenge is coldness [2,42]. Subjects report more often
the feeling of freezing, and they exhibit cooler extremities
[43] and even cooler corneas than others when exposed to
coldness [44]. Another trigger factor is psychological
stress [45]. The way our body responds to this stress
seems to be individually different [46] and also gender
dependent [47]. Subjects with PVD often respond with
redistribution of BF. These persons may get cold hands
during stressful periods. To give an example, we
performed a nailfold capillary microscopy test on a female
musician suffering from NTG, a condition associated with
PVD. While baseline BF in the capillaries was normal and
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her cold-induced BF stop lasted only a few seconds, the
BF in the nailfold capillaries stopped for about 3 min
when she started to talk about problems with her
husband. Additionally, we observed a more heterogeneous
distribution of temperature during psychological stress in
thermography of the face as well.
In addition to cold and emotional stress, there are
many other trigger factors. While some PVD subjects
respond more to one particular trigger, others respond to
multiple triggers. Vibration is another stimulus leading to
vasoconstriction in some people [48], interestingly not only
in the exposed but also in the unexposed hand [49].
Such people cannot work with a compressor [50].
Workers with hand-arm vibration syndrome also
suffer from cold-induced vasospasm [51], indicating
an underlying predisposition. Rarely do subjects with
PVD respond to physical exercise. We made the
observation that PVD subjects tend to suffer longer
and stronger from whiplash traumata than others.
Indeed, reduced cold pain threshold (cold hyperalgesia)
predicted a worse outcome after whiplash traumata [52,53].
3.1.4 PVD and Raynaud's disease
PVD [1] and Raynaud's disease [54] have certain similar-
ities, which is why they are often confused with each other.
In his thesis, written in 1892, Raynaud described an illness
involving local ischaemic of the hands. This led to the term
Raynaud's disease. In Raynaud's disease, the fingers turn
white, which is why it is sometimes called the ‘white finger
disease’ or ‘corpse finger disease’ (Figure 4). In addition,
Raynaud's disease leads to morphological changes in the
fingertips. Raynaud's disease is therefore distinctly different
from PVD. Later, the term Raynaud's phenomenon was
coined to describe a similar but clearly weaker entity than
Raynaud's disease. Raynaud's phenomenon can also be
primary or secondary [55]. The symptoms of Raynaud's
phenomenon are to some extent similar to those of PVD
[54]. The hands of PVD subjects indeed are also cool, but
in contrast to Raynaud's syndrome, they almost never turn
totally white and are not numb. In addition, the onset of
symptoms is not so abrupt and lasts longer than in
Raynaud's phenomenon. PVD patients also suffer from a
variety of other symptoms which do not occur in Raynaud's
phenomenon. Therefore, PVD syndrome should not
be confused with Raynaud's disease or with Raynaud's
phenomenon. Additionally, both Raynaud's disease
and Raynaud's phenomenon, in contrast to PVD, are only
weakly related to glaucoma. Furthermore, PVD is also not
identical with the so-called purple digit syndrome [56].
3.2 Secondary vascular dysregulation
BF to an organ can be dysregulated in diseases affecting the
corresponding organ and also in diseases affecting remote
organs. If a vascular dysregulation is secondary to such a
disease, it is called secondary vascular dysregulation [1].
SVD in this context should not be confused with
small vessel diseases.
3.2.1 Mechanism of SVD
In various conditions, particularly in inflammatory diseases,
there is a release of molecules into the corresponding tissue
and partially also into the blood stream, leading to changes
of molecule concentration in the circulating blood that
affects remote organs. Well known is the release of tumour
necrosis factor-alpha which, among many effects, influences
temperature control in the hypothalamus, thereby inducing
fever. In a similar way, other molecules influence vascular
tone; among these molecules, the most important is ET-1.
ET-1 is produced by the vascular endothelium cells and is
released predominantly abluminally and only partially
intraluminally [58]. Under stress conditions, however, other
cells also start to produce ET-1 [59] and thereby influence
its concentration in the circulating blood. An increase in
ET-1 has little or no effect on brain or retinal circulation as
long as the blood–brain or blood-retinal barrier is intact
[60]. In case of blood–brain or blood-retinal barrier break-
down, ET-1 gets direct access to smooth muscle cells or
pericytes, thereby leading to vasoconstriction. As no such
barrier exists in the choroid, an increase in ET-1 reduces
choroidal BF. There is also a ‘physiological barrier defect’
in the ONH because molecules can diffuse from the chor-
oid into the ONH [25] (see Figure 3). This explains ONH
BF reduction in all conditions with increased ET-1 plasma
levels.
3.2.2 Causes of SVD
We will discuss a few diseases which can lead to increased
ET-1 plasma levels.
Multiple sclerosis. In patients with multiple sclerosis
(MS), monocytes produce ET-1, thereby increasing its
concentration in the cerebrospinal fluid (CSF). ET-1
levels are significantly elevated in the CSF of relapsing
remitting MS patients with an acute clinical attack in
Figure 4 Raynaud's disease versus PVD. (Left) Hand of a healthy
person. (Middle) Hand of a PVD subject. (Right) Hand of a patient
with Raynaud's disease. (From [57], with permission).
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comparison with those in a stable phase [61]. In some
MS patients, ET-1 in the circulating blood [62] is
increased, and therefore, ocular blood flow (OBF)
decreased (Figure 5). This might contribute to the loss
of retinal ganglion cells and their axons [63], to
subclinical visual field defects [64], to narrower retinal
arterioles and wider venules [65] and to increased
rigidity of the retinal vessels [66]; furthermore, it may
partially be the reason the ONH can turn slightly pale.
Red wine can reduce ET-1 concentration which
therefore explains why certain symptoms like visual
disturbances in MS patients are reduced by red wine
for a limited period of time [67]. The observed
breakdown of the blood–brain barrier in these patients
might also partly be due to ET-1 [68].
Optic neuritis. During optic neuritis, the blood ET-1
level rises quickly and then drops slowly during the next
weeks but often remains slightly above normal values
[70]. The reason for this increase during optic neuritis is
not clear. Most likely, it is due to an increased
production of ET-1 by monocytes. Whether ET-1
contributes to the symptoms is not clear at present.
Rheumatoid arthritis. Patients with rheumatoid
arthritis have moderately increased plasma levels of
ET-1 [71] produced, partly, by activated synovial
cells [72]. ET-1 lowers the threshold of pain
sensation. The mechanical hyperalgesia lasts longer
in females [73], and ET-1 receptor blockade reduces
pain [74].
Fibromyalgia. Some patients with fibromyalgia have
increased levels of ET-1, although we do not know
why [75]. It is also not known whether this plays any
role. Nevertheless, by influencing the pain sensation
threshold, the increased level of ET-1 presumably
contributes to the pain sensation of these patients.
Giant cell arteritis. Giant cell arteritis is a systemic
vasculitis affecting large and medium-sized arteries.
The arteritic lesions lead to ischaemic symptoms
such as cephalgia, masseter pain and mental
depression. The acute loss of visual function is most
often due to anterior ischaemic optic neuropathy
and less frequently due to a central artery occlusion.
Giant cell arteritis patients with involvement of the
visual system have increased ET-1 plasma levels
[76,77]. In inflamed temporal arteries, not only is
the ET-1 level increased but also the expression of
ET receptor B is upregulated both in vascular
smooth muscle cells and multinucleated giant cells
[78]. The involvement of the endothelin system
explains why BF is reduced to a greater extent in the
choroid than in the retina [79], why infarctions
occur more often in the ONH than in the retina and
also why amaurosis fugax-like symptoms often
precede the major event [80]. The increased levels of
ET-1 may be partly due to the matrix
metalloproteinases (MMP2) released during
inflammation. MMP2 converts the precursor
molecule Big ET-1 to the active ET-1.
Retinal vein occlusion. Most patients with retinal
vein occlusions have increased plasma levels of ET-1
during the acute phase. Weeks or months later, the
concentration decreases, but rarely normalises
totally [81,82]. The cause is unclear. The fact that
the majority of patients suffer from other diseases
such as systemic hypertension, diabetes or glaucoma
makes it probable that these diseases may have
caused or at least contributed to the increase of
ET-1 plasma levels. PVD is another cause. For this
reason, vein occlusions will be discussed in the
section on PVD. The occlusion of the retinal vein
seems to be often a secondary consequence of a
retinal hypoperfusion due to an arterial disease.
This leads to tissue hypoxia and thereby to an
increase in HIF-1α (Figure 6).
HIF-1α then increases the expression of several factors
like VEGF, erythropoietin and ET-1. An increased
concentration of ET-1, both in the circulating blood
and locally in the retinal tissue, can induce venous
constriction and thereby increase retinal venous
pressure [84]. If this pressure increases further, a pre-
stasis syndrome and eventually the clinical picture of
retinal vein occlusion (also called retinal venous
thrombosis) develop. Indeed, ET-1 injection into the
vitreous occludes the veins [85].
Others. Secondary vascular dysregulation may
occur also in patients with antiphospholipid
syndrome, pre-eclampsia, Susac syndrome and
Figure 5 Endothelin-1 in multiple sclerosis patients. In some
patients with multiple sclerosis, the plasma level of ET-1 (mean ± SEM)
is increased (left; modified from [62]). This leads to a decrease of OBF.
Peak systolic and end diastolic velocity (cm/s) in the medial posterior
ciliary arteries (mean ± SEM) in the corresponding MS patients (right;
from [69], with permission).
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central serous chorioretinopathy. However, based
on their medical history, these subjects also often
suffer from PVD syndrome before they get sick;
therefore, some of these diseases will be discussed
in the context of PVD.
4 General symptoms and signs of PVD
Although the most striking signs and symptoms in PVD
subjects are directly related to the dysregulation of BF,
these subjects often have additional signs and symptoms
only indirectly related or seemingly even unrelated to BF.
These signs and symptoms are not specific for PVD
subjects but occur significantly more often in PVD subjects
than in non-PVD subjects. The knowledge on these signs
and symptoms helps in understanding these subjects better
and might influence recommendations for behaviour as
well as treatment of such patients.
4.1 General symptoms of PVD
4.1.1 PVD and temperature sensation
Classically, PVD patients indicate that they often feel cold,
particularly in the hands or feet. Cold hands can be pro-
voked not only by coldness but also by emotional stress, by
vibration or via vasoconstrictive drugs; interestingly, the
sensitivities to these trigger factors are interrelated. For ex-
ample, emotional stress increases drug sensitivity, and pa-
tients that respond to vibration also have higher probability
to respond to coldness [51,86,87]. An epidemiological
study analysed thermal discomfort with cold extremities in
a Swiss urban population. Younger subjects suffered more
intensively from cold extremities than elderly subjects,
women suffered more often than men, and slim subjects
suffered more often than those with higher body mass
index [33]. Psychological stress leads to vascular dysfunc-
tion, even in animals [88,89]. Subjects with PVD, however,
seem to respond stronger to psychological stress than
non-PVD subjects. There is also a relationship be-
tween cold extremities and sleep behaviour, which will
be discussed in the section 4.1.3.
4.1.2 PVD and thirst
The desire to drink is significantly lower in subjects with
PVD, while estimated daily fluid intake is only slightly
lower [27]. However, PVD subjects tend to forget to drink.
The concentration of ET-1 in the circulating blood is
slightly increased [27], and this (among other effects) sup-
presses - via the prostaglandin-E2 axes - the centre of thirst
in the brain. Reduced feeling of thirst, however, occurs also
in patients with other diseases in which ET-1 concentra-
tion in the circulating blood is increased. For example, MS
patients typically indicate that they are not thirsty and
drink simply because they know they have to drink.
4.1.3 PVD and sleep behaviour
PVD subjects often indicate that they require a long time
to fall asleep, particularly when their feet are cold. Indeed,
studies have shown that body temperature and sleep are
interrelated [90]. Sleep is typically initiated when central
body temperature is declining and body heat loss on the
extremities is maximal. This indicates that we fall asleep
only after our extremities, particularly our feet, are
warmed up, and this takes longer on average in subjects
with PVD (Figure 7). Melatonin is one factor involved in
the fine-tuning of vascular tone in selective vascular beds
[91], and PVD subjects have circadian phase delay of dim-
light melatonin onset [92].
Figure 7 Sleep onset in PVD patients. (Left) Sleep onset time in
PVD subjects is longer than in controls. This is due to the link
between sleep onset and redistribution of temperature (modified
from [90], with permission). (Right) Mean foot skin temperature
before and during sleep. The delay in warming up of the feet
explains the delay in sleep onset time (Courtesy of Kräuchi K).
Figure 6 Hypoxia-inducible factor-1α. If oxygen concentration in
a cell is lowered, less HIF-1α is oxidised and degraded. Thus,
stabilised HIF-1α moves into the nucleus of the cell, where it acts as
a transcription factor, stimulating the production of ET-1 or VEGF.
(From [83], with permission.)
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4.1.4 PVD and physical activity
Physical activity and mechanical stimuli can, in some
PVD subjects, provoke local vasospasm. Examples are
algodystrophy or acute posttraumatic ischaemic of the
limbs [93], exercise-induced amaurosis fugax-like
symptoms [94] due to vasospasm of the retinal arteries,
painful and ischaemic mammilla provoked by nursing
[95,96] or orgasmic headache due to transient vasospasm
[97-99]. All these symptoms fortunately occur infrequently.
Most PVD subjects tolerate physical activities and are
physically even more active than non-PVD subjects,
particularly in endurance sports like cycling or running.
4.1.5 PVD and professional activity
Subjects with PVD are generally very meticulous. They tend
to be very exact and diligent, particularly at work. They are
often successful in their careers. Interestingly, there are
more PVD subjects amongst the academics than amongst
blue-collar workers. We observed only very few farmers or
gardeners with PVD syndrome. Furthermore, we made the
observation that black Africans developed the symptoms of
PVD only after moving from Africa to Europe. At present,
we do not have an explanation for this relationship. One
hypothetical explanation is light exposure. Vitamin D may
play a role, but has not yet been studied.
4.1.6 PVD and sensitivity
Based on clinical experience, PVD subjects are generally
more sensitive. PVD subjects, for example, are able to
smell odours that others cannot [100] (Figure 8), and
they do have a higher pain sensation. Some PVD
subjects perceive thunderstorms as well as foehn
weather situations stronger than non-PVD subjects.
It is our clinical experience that PVD subjects also
have a higher sensitivity to certain drugs. They tolerate
these drugs well but often only when given at much lower
doses. This might partly be explained by the different
expressions of certain ATP binding cassette (ABC)
transporter proteins [101] (Figure 9).
The vascular response to nicotinates is increased
[102]. We observed a young PVD patient who lost the
tips of his fingers and nose after receiving an infusion
containing adrenalin to treat arterial hypotension, which
occurred in the context of an infection. Although the
clinical observations are quite consistent, all these
aspects have not yet been studied sufficiently.
4.1.7 PVD and psychological stress
Not much is known about the stress level of people with
PVD. However, they tend to react differently to stress,
particularly by reducing BF to the extremities and to the
eyes [103]. In extreme situations, this can even lead to
an infarction (e.g. an infarction of the ONH). We
observed ONH infarctions in two stock market traders
when share values dropped dramatically and in one
student who failed an exam. A schoolgirl suffered from a
retinal arterial branch occlusion after a major stress.
We often observed retinal venous occlusion in PVD
subjects after major psychological stress (see ‘Retinal
vein occlusion’). In some subjects with PVD, an
increased heterogeneity of skin perfusion, e.g. in the
face, can be observed by eye but even better with the
help of a thermal camera. Emotions can also provoke
reversible cerebral vasoconstrictions [104].
4.1.8 PVD and pain
We already discussed pain sensitivity. Some PVD
subjects also suffer from muscle cramps and other
Figure 8 PVD subjects are good smellers. ‘Sniffin' Sticks’ score in
healthy (left) and normal-tension glaucoma patients (right) with and
without PVD. (Modified from [100], with permission).
Figure 9 The role of transport proteins: MDRI (P-glycoprotein)
and MRP (multidrug resistance-associated protein). The mean
expression of these genes is significantly different in PVD subjects in
relation to healthy controls. (Modified from [101], with permission).
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pain. Sometimes they feel pain deep in their eyes
(behind the upper eyelid), which most likely is due
to ischaemic of the ciliary muscle. These eye pains
vanish quickly after treatment with a calcium channel
blocker (CCB) such as nifedipine.
4.1.9 PVD and migraine
PVD and migraine are not identical and should not
be confounded. Although PVD subjects suffer more
often from migraine and vice versa, the two entities
are principally independent [105]. While patients with
migraine often have thermal hypersensitivity between
attacks [106], a migraine attack can trigger the symptoms
in a PVD subject, such as cold hands in the phase of aura.
A reduction of neurovascular coupling during the acute
phase has also been reported, potentially explaining
why migraine patients avoid both intensive light and
noises [107,108].
PVD subjects sometimes - but not often - suffer
from retinal migraine, also called ‘presumed retinal
vasospasm’ [109]. Retinal ‘angiospasm’ during migraine
has already been described in 1910 [110]. In 1939, a
relationship between retinal vasospasm and alterations in
the nailfold capillaries was described [111]. Such focal
retinal arteriolar vasospasm can be dynamic with spastic
cycles of a few seconds [112] (Figure 10). The reversible
vasoconstriction in the retina [113] indicates that there
must exist stimuli for vasoconstriction other than the
autonomic nervous system. Taking neurovascular
coupling into consideration, it seems feasible that a
spreading depression [114] acts as a trigger factor for
the vasoconstriction.
4.1.10 PVD and altitude sickness
Altitude sickness is a general term encompassing a
spectrum of disorders that occur at higher altitudes.
Most individuals suffer from altitude sickness to some
extent when they reach high altitudes within a short
time without giving their body enough time to adapt.
Potential symptoms are as follows: headaches, lack of
appetite, nausea, vomiting, fatigue, dizziness, sleep
disturbances and peripheral oedema. The eyes are often
involved. BF disturbances and retinal bleeding may
occur. There is evidence for a genetic basis for altitude
sickness [115].
The major cause of altitude sickness is the low oxygen
level at higher elevations that leads to tissue hypoxia and
thereby to an increase of HIF-1α. This induces increased
expression of several hormones, including erythropoietin
and also ET-1. Carbonic anhydrase inhibitors, endothelin
antagonists and CCBs alleviate the symptoms. In the
long term, our body acclimates to this situation, for
example, by building more red blood cells. Based on our
still-ongoing studies, we can state that the symptoms of
altitude sickness are more pronounced in PVD subjects.
We observed a young female subject with a known PVD
syndrome who lost consciousness on a hot air balloon
ride over the Alps. At high altitude, we also observed an
increase in the retinal venous pressure, which is most
likely a consequence of the rise of ET-1 [116].
4.1.11 PVD, tinnitus and sudden hearing loss
PVD subjects with NTG often indicate suffering from
tinnitus and remarkably often indicate a history of
sudden (mostly reversible) hearing loss [117]. Hearing
problems in the context of migraine have been
described [118], but the relationship between hearing
and PVD needs to be studied. Nevertheless, the presence
of ET receptors in the spiral modiolar artery makes a
relationship probable [119]. The majority of patients
with sudden hearing loss, despite apparent good
health, have signs of disturbed microcirculation in
the eye [120]. In addition, auditory processing deficits
occur more often in individuals with primary open-angle
Figure 10 Retinal migraine. Fundus photograph taken during an
attack of a retinal migraine (top). Area of focal dynamic spasm along
the right superior temporal branch retinal artery. Photographs (A, B,
C, D) represent different phases of the cycle (middle and bottom).
(From [57] (top) and [112] (middle and bottom), with permission).
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glaucoma [121], supporting the concept of glaucoma as a
sick eye in a sick body [122].
4.1.12 PVD and thyroid dysfunction
Hyperthyroidism may induce coronary vasoconstriction
[123,124], and treatment with L-thyroxine can induce
coronary spasm [125]. Hypothyroidism also can be
associated with vascular dysfunction such as impaired
endothelial- and non-endothelial-mediated vasodilation
[126]. Hypothyroidism is associated with NTG [127],
and interestingly, we find thyroid antibodies in most of
these NTG patients. The vast majority of such patients
are PVD subjects. An association between Raynaud's
phenomenon and hypothyroidism was also described
[128]. The causal relationship is not yet clear. Theoretically,
ischaemic lesions in the thyroid gland may stimulate an
autoimmune process or, conversely, autoimmunity may
cause secondary vascular dysfunction.
4.2 General signs of PVD
In addition to the above illustrated symptoms, several
signs characterise PVD subjects. These signs, which
can be quantified objectively, will be summarised in
the following paragraphs.
4.2.1 PVD and temperature
The sensation of cold extremities, a leading PVD symptom,
is confirmed by finger skin temperature measurements
[29,87]. PVD subjects are characterised by a lower
distal (hands and feet) skin and corneal temperature
(Figure 11). In some PVD subjects, the temperatures
are asymmetric (Figure 12).
However, proximal skin temperatures of PVD subjects
do not differ significantly from other subjects. Furthermore,
in the circadian rhythm, PVD subjects also show a phase
delay in foot skin temperature in comparison to non-PVD
subjects [129]. Reduction of temperature due to vasospasm
can occur anywhere on the body surface, not only on the
hands, feet or nose but also at the scrotum [130] or the
mammillae [131]. Interestingly, corneal temperature
correlates well with BF of the ophthalmic artery
[132,133] and with finger temperature even after adjusting
for environmental and tympanic temperatures and for age
and sex [44].
4.2.2 PVD and endothelin-1
ET-1 is a peptide produced mainly, but not only, by
endothelial cells. It is secreted abluminally to
regulate local vascular tone. A small part is secreted
intraluminally, leading to a certain concentration of
ET-1 in the circulating blood (Figure 13). Production
of ET-1 in other cells, particularly under pathological
conditions (see ‘Secondary vascular dysregulation’),
further contributes to the plasma level. After the
binding of ET-1 to its receptor, the complex is internalised
into the cell. A major stimulation by ET-1 is therefore
followed by a refractory phase (Figure 14).
Circulating ET-1 is mainly eliminated in the lung.
Plasma level of ET-1 therefore reflects the balance
between production and elimination of ET-1 and thus
represents, to some extent, local activities. In healthy
Figure 11 Examples of thermography of the hands, faces and
eyes of controls (left) and PVD subjects (right). (From [57],
with permission).
Figure 12 Thermography picture of the feet of a PVD subject
with asymmetric temperatures.
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PVD subjects, ET-1 is slightly increased [27]. Both
increased [135-138] and normal circulating ET-1
plasma levels [139] have been described in NTG
patients. In one study, ET-1 was higher in those with
progressive ONH damage than in those in which the
damage has stabilised [140]. Other authors found a
normal ET-1 level at baseline, but an abnormal
response with changing body position [141] or after
cold provocation [142]. There are conditions in which
local ET-1 concentrations do not correspond to the
plasma level, for example, in the aqueous humour of
glaucoma patients [139]. Notably, ET-1 in the aque-
ous humour correlates with IOP but not with sys-
temic ET-1 plasma level [143]. Thus, in NTG
patients, ET-1 may have a local as well as a systemic
role, while in high-tension glaucoma (HTG) patients
ET-1 may be dominantly increased to ocular tissue.
Overall, for an adequate vascular function, the
balance between vasoconstrictors (particularly ET-1)
and vasodilators (particularly NO) [39] is of importance.
In addition to the local concentration of ET-1, the local
sensitivity to ET-1, which in turn depends on the number
of ET receptors, is of importance as well [134,144].
Receptor density is locally increased in patients with giant
cell arteritis. Interestingly, ET sensitivity is also dependent
on blood pressure (BP). PVD subjects with low BP have
higher ET-1 sensitivity [145]. Polymorphism of the ET
receptor A seems to be associated with NTG [146]. A
variant of the ET receptor A gene also modulates the risk
for migraine [147]. Corresponding studies with healthy
PVD subjects have not been done yet.
4.2.3 PVD and blood pressure
Aside from cold extremities, low BP is a characteristic
of PVD subjects, especially when they are young. The
diurnal pattern of the mean arterial pressure nearly
mirrors the distal minus the proximal skin temperature
gradient, providing a measure for distal skin BF. In other
words, diurnal BP variations are associated with changes
in distal-proximal skin temperature gradients. Therefore,
subjects with cold extremities (particularly PVD subjects)
mostly have lower BP than control subjects [148].
Figure 13 Endothelin-1. ET-1 is a 21-amino acid peptide (left) secreted from endothelial cells predominately abluminally and to a lesser extent
intraluminally (middle). Endothelin receptor A (ETRA) is located on smooth muscle cells and mediates vasoconstriction whereas ETRB is on both
the smooth muscle cells and the endothelial cells and has a more neutral effect. (Modified from [83], with permission).
Figure 14 Refractoriness to ET-1. After the first stimulation by
ET-1, subsequent stimulations lead to a smaller response. The first
response is arbitrarily defined as 1, while subsequent responses are
less than 1. The vessels recover within about 4 h. (From [134],
with permission).
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Glaucoma patients with PVD also have lower mean
daytime BP (Figure 15).
BF standstill in the nailfold capillaries is often used as
the gold standard for the diagnosis of PVD (Figure 16).
Interestingly, BF standstill in the nailfold capillaries after
cold provocation was negatively correlated with the low-
est systolic BP at night (dipping) [149]. Conversely, pa-
tients with nocturnal over-dipping had reduced
retrobulbar BF with increased resistivity [150]. Systemic
hypotension and PVD occur more often in young
females than in postmenopausal women or in men. It
was suggested that local β-adrenergic vasodilatation may
offset α-adrenergic vasoconstriction in women to a
greater extent than it does in men [151]. NTG patients
have reduced sodium reabsorption in the proximal
tubule, in spite of a low BP [152], probably also influenced
by the slightly increased ET-1 level [153].
4.2.4 PVD and the heart
The role of vascular dysfunction in the development,
progression and prognosis of atherosclerosis has been
well documented [8]; however, vascular dysfunction is
not pathognomonic for atherosclerosis. Chest pain or
ischemia despite structurally normal, non-atherosclerotic
coronary arteries is quite common, particularly in women,
and may represent local dysregulations of the epicardial
or the microcirculatory coronary vessels. Coronary
vasospasms of apparently healthy arteries were
described by Prinzmetal in 1959 [154]. Such spasms
of the epicardial arteries occur at rest or after certain
provocations, sometimes triggered by psychological
stress [155]. Interestingly, the typical reduction or
even stop in BF in the nailfold capillaries of PVD
subjects in response to local cooling is also seen in
patients with vasospastic angina [54]. Furthermore,
vasospastic angina is far more common in Asian
countries [156], a pattern similar to both PVD and
NTG [157]. Microvascular angina, particularly present
in women, is another entity associated with dysfunctional
vessels, particularly in the microcirculation [158]. However,
it more likely affects elderly women with cardiovascular
risk factors, thus a population different from those with
PVD. However, microvascular angina may be an umbrella
term for several vascular diseases, and PVD may be
responsible for symptoms in a subset of these patients,
especially in those where an abnormal increased pain
sensitivity is proposed to be the pathomechanism [159].
An interesting observation in PVD patients is that
electrocardiogram changes typical for myocardial
ischemia occur frequently when patients are monitored
over 24 h, thus silent ischemia could take place in these
patients, particularly at night [160,161]. Interestingly,
disorders associated with secondary elevation of ET-1
and SVD, such as rheumatoid arthritis or psoriasis,
show endothelial dysfunction and a significantly higher
cardiovascular mortality [162,163].
4.2.5 PVD and the autonomic nervous system
Vascular dysregulation is often explained by autonomic
nervous dysfunctions. Indeed, analysis of heart rate vari-
ability revealed an autonomic imbalance in healthy PVD
subjects with sympathetic predominance [164] (Figure 17).
This is in agreement with the observation of a shift in the
sympathovagal balance of the autonomic nervous system
of NTG patients towards sympathetic activity [165].
Furthermore, PVD subjects show an increased reactivity
in the well-innervated choroid [166]. PVD subjects also
show a temperature dysregulation in the extremities and
in the sympathetically innervated skin. This also explains
the influence of emotions (including anxiety) on skin
perfusion [37,167]. This was indirectly confirmed by a study
comparing slow and normal hand re-warmers. Slow re-
warmers demonstrated less activity in the parasympathetic
nervous system during the cold provocation protocol
compared to normal re-warmers [168]. Dysfunction of
the autonomic nervous system in NTG patients [169]
was related to ET-1 levels [170].
The exact causal relationship between autonomic
nervous dysfunction and vascular dysfunction is un-
clear. A dysfunction of the autonomic nervous system
can induce dysregulation of vessels. On the other
hand, vascular dysregulation leads to chronic intermit-
tent hypoxia, and this in turn increases sympathetic
nervous activity chronically [171]. The involvement of
the non-innervated retinal vessel, however, demon-
strates that although the autonomic nervous system is in-
volved, it cannot be the only player in the pathophysiology
of PVD.
Figure 15 Daytime BP of glaucoma patient with PVD. (Left)
Example of a 24-h blood pressure profile of a PVD subject (red) in
relation to a control subject (grey). (Right) The reabsorption of
sodium in the proximal tubule of the kidney (asterisk) is most
probably reduced by the activation of PG E2 via ET-1. (Modified from
[57], with permission).
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4.2.6 PVD and circadian rhythm
Circadian rhythm and thermoregulation are interconnected
phenomena [172]. The human body consists of two
compartments, the heat-producing core and the heat-losing
regulating shell. Even in a comfortable thermo-neutral
environment, heat produced by the core is transferred to
the peripheral parts of the body, which serve the function
of heat loss. These parts are distal skin regions - fingers and
toes. Heat loss is autonomically regulated and occurs via
constriction or dilatation of peripheral blood vessels [173].
There is a close link between body heat loss and sleep
induction. When falling asleep, the core body temperature
declines, while distal skin temperature increases, indicating
heat redistribution from the core to the shell. The degree of
peripheral blood vessel dilatation of the skin of the hands
and feet is a good physiological predictor for the rapid
onset of sleep [174]. There is a strong association between
thermal discomfort from cold extremities and sleep onset
latency in the general population [29]. It has been
shown that PVD subjects with sleep onset insomnia
exhibit a phase delay of the circadian system (circadian
rhythms of distal and proximal skin temperatures, core
body temperature and salivary melatonin secretion) by
approximately 1 h, but no differences in overall sleep
times [92] (Figure 18).
4.2.7 PVD and gene expression in lymphocytes
Cells adapt their gene expression depending on internal
and external information. Gene expression therefore
reflects, at least to some extent, the environment in
Figure 16 Nailfold capillary microscopy with a cooling device. The nailfold is made transparent by a drop of oil and is then videotaped (left).
Normal blood flow (middle) and flow stopping after cold provocation (right). (Modified from [57], with permission).
Figure 17 Power spectrum of heart rate variability. (Red)
Average of PVD subjects and (blue) average of controls. VLF, very low
frequency band; LF, low frequency band; HF, high frequency band.
Paced breathing at 0.2 Hz. (Modified from [164], with permission).
Figure 18 Phase delay of the circadian system in PVD subjects
in relation to normal controls. (A) Melatonin concentration in the
saliva, (B) temperature gradient (distal minus proximal skin temperature)
and (C) core body temperature within a 24-h period without sleep. The
delay is approximately 1 h. (Modified from [92], with permission).
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which these cells live. Circulating lymphocytes are not
only easily accessible but also circulate through the
whole body and are therefore good candidates to
compare populations. Indeed, the gene expression profil-
ing of PVD subjects revealed significant differences from
non-PVD subjects but is very similar to that of glaucoma
patients [175,176] (Figure 19). The genes and gene products
of interest as potential diagnostic and drug targets have
been summarised in other review articles [177,178].
4.2.8 PVD and oxidative stress
Reactive oxygen species (ROS) play a major role in both
physiology and pathophysiology. If production of ROS
exceeds its elimination capacity, oxidative stress results.
Oxidative stress can be local or more generalised.
Because PVD leads to unstable BF and thus to an unstable
oxygen supply in certain organs, ROS productions may be
triggered (Figure 20).
The majority of PVD subjects, especially when they
are young, can cope with oxidative stress and do not
develop tissue damage. Patients suffering from both
PVD and glaucoma show a higher number of DNA
breaks in their circulating lymphocytes (quantified by
comet assay), indicating that oxidative stress is present
even systemically [179,180] (Figure 21). In glaucoma,
oxidative stress occurs mostly in the mitochondria of the
retinal ganglion cells and their axons. Research,
therefore, is focused on developing strategies to
maintain mitochondrial function [181].
5 Visual signs and symptoms of PVD
5.1 PVD and visual function
Most healthy subjects with PVD do not complain of visual
disturbances, though some rarely indicate scintillation. In
contrast to this perception, quantitative perimetry shows
fluctuating visual defects in many subjects with PVD
[30,45,182,183]. These are commonly diffuse defects best
visualised by the Bebie curve [184] (Figure 22).
However, some researchers have first questioned
whether changes in OBF lead to changes in visual
function. Experimental studies in a pressure chamber
then revealed that mean visual sensitivity is indeed
directly and quickly influenced by oxygen saturation
[185]. Although not felt, the differential light sensitivity
decreased as oxygen concentration dropped. Visual fields
reveal short- [186] and long-term [187] fluctuations.
Certainly, long-term fluctuation is increased in PVD
subjects [188]. Interestingly, if glaucoma patients with
PVD show visual field defects, then only the diffuse
component of the defect fluctuates [1,189].
Figure 19 Differential proteomics imaging of circulating lymphocytes. (Top) A pathology-specific protein cluster is completely suppressed
both in NTG patients and in healthy PVD subjects versus controls. (Bottom) The marked protein (SSP2602) is highly upregulated both in NTG
patients and in healthy PVD subjects compared to the expression profile of controls. (Modified from [176], with permission).
Figure 20 Activation of ground state oxygen. Ground state
oxygen is relatively inert due to a parallel spin of two free electrons
(spin restriction). Oxygen can be activated by adding energy, turning
one spin. This leads to singlet oxygen. Oxygen can also be activated
by adding one single electron, leading to superoxide. This is
particularly the case in the mitochondria during reperfusion.
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5.2 PVD and ocular blood flow
It is known that the circulation in the extremities or the
heart may react with vasospasm [156]. Rather surprising
is the fact that the eye can react with inadequate
vasoconstrictions as well. In 1910, Blessing and Amburger
described retinal angiospasms during migraine [110]. In
1939, Lisch described functional vascular dysregulations of
the eye and recognised a relationship with a dysregulation
of the finger capillaries [111]. In 1948, Traquair observed
spasm in the central retinal artery [190]. Incidentally, at
that time, the visual symptoms of Adolf Hitler were
interpreted by his physician as being of vasospastic origin
[191]. In 1986, we described an involvement of the eye in
primary vasospastic syndrome (we call it PVD today)
[182,183]. We also described the assumption that
vasospasm might be involved in the pathogenesis of
glaucomatous damage [192] and discussed the potential
role of CCBs to treat this condition [193].
At that time, it was difficult to measure OBF in
humans, and our suppositions therefore were mainly
based on the quantitative relationship between visual
function and peripheral BF. The measurement of OBF is
still challenging [194], and reliable methods have been
made available only recently [4,195]. From a historical
prospective, it is interesting that the hypothesis of
PVD affecting OBF was based on the analogy of
nailfold capillaries [2] and visual field behaviour
[188,196]. In PVD subjects (but not in others), there
was a significant correlation between nailfold capillary
BF and visual fields. After cold provocation, both the
nailfold capillary BF and the visual field deteriorated;
likewise, after an intake of CCBs [197], both nailfold
capillary BF and the visual fields improved.
It was debated as to what extent the observed visual
field improvement in PVD subjects after treatment with
a CCB may be due to the improved OBF or rather a
direct effect of these drugs on neural tissue [198]. How-
ever, a similar visual field improvement has been observed
with other OBF-improving drugs, such as with carbonic
anhydrase inhibitors [199] and even with CO2 breathing
[200]. It has also been shown that the same people
responding well to CO2 also respond well to CCBs;
Figure 21 One possibility to estimate oxidative stress is DNA break quantification by comet assay analysis. (Left) Example of
lymphocytes of a healthy subject. (Middle) Lymphocytes of a patient with glaucoma and PVD. (Right) Mean number of the breaks (quantified as
tail moment) demonstrating an increase of DNA breaks in subjects suffering from both glaucoma and PVD. (From [180], with permission).
Figure 22 Examples of visual fields (Octopus program G1) presented by greyscales and the corresponding Bebie curves. (Left) Healthy
control and (right) healthy PVD subject.
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additionally, subjects responding well to CCBs in the short
term also respond well in the long term [201]. In contrast
to non-PVD subjects, in PVD subjects, OBF is directly
related to ocular perfusion pressure [202,203], indicating a
disturbed autoregulation [204] of ocular perfusion in PVD
subjects. Although BF velocity in the periphery [2] and in
the ocular circulation is decreased on average, BF in
individual PVD subjects can be normal under base-
line conditions. However, a cutaneous cold provocation
induces an immediate decrease in retinal and ONH perfu-
sion, and this decrease diminishes or disappears quickly
when the hand is immersed in warm water [205]. In PVD
subjects examined with colour Doppler imaging, the peak
systolic and end diastolic velocities and the resistivity index
of the central retinal artery significantly correlated
with the mean ocular perfusion pressure [206]. In
glaucoma patients with PVD, BF in the choroid and
ONH is reduced compared to glaucoma patients
without PVD [207]. More details will be discussed in
the section 6.1.
5.3 PVD and retinal vascular spatial irregularities
Healthy PVD subjects showed higher spatial irregularities
in retinal vessels than non-PVD subjects [208]; in other
words, retinal vessels of vasospastic subjects are less
smooth. This indicates that the mechanism of dysregulation
(particularly endothelium dysfunction) is not homogenous
along the vessels. It rather affects different parts of the same
vessel stronger than other parts. This irregularity is
not identical to overall retinal arteriolar narrowing,
which, interestingly, is an important risk factor for
open-angle glaucoma [209].
5.4 PVD and stiffness of retinal vessels
Vessels become stiffer when they become sclerotic.
Interestingly, pulse wave propagation in the retinal
vessels of PVD subjects is faster, indicating that they
are stiffer without recognisable morphological alter-
ations [210]. This is also the case in untreated NTG
patients [211].
5.5 PVD and neurovascular coupling
Flickering light to the retina leads to a dilation of both
retinal arteries and veins within seconds (Figure 23).
This response is reduced in healthy PVD subjects [11].
The cause of this is not yet clear. Most probably, it is
mainly due to an altered function of the vascular
endothelial cells in PVD subjects (see ‘The role of
vascular endothelial cells’). Interestingly, the general
vessel response to flickering light was also decreased
in POAG patients [12].
5.6 PVD and the blood–brain barrier
The central nervous system (including the retina) is a
very sensitive system. Specialised structures, such as
tight junctions between endothelial cells, are required to
maintain a stable environment and to ensure appropriate
neuronal activities [212]. The barrier in the ONH,
however, is physiologically incomplete as a result of (a)
diffusion from the fenestrated capillaries of the choroid
into the ONH (see Figure 3) and (b) a nonspecific
permeability of the capillaries, possibly mediated by
vesicular transport [24]. The blood-retinal barrier is
highly regulated, and this involves molecules such as
ET-1 that are also involved in the regulation of vascular
tone [213]. Expression of ET-1 is increased under
hypoxic conditions, either locally in the retina, affecting
retinal vessels, or systemically, thereby influencing the
barrier in the ONH and adjacent retina by diffusion
from the choroid. PVD can lead to hypoxia and thereby
indirectly to barrier dysfunction. This is of special interest
for glaucoma [26,178].
Figure 23 Retinal vessel analyser registers the size of a selected retinal artery and vein. Flickering light (green bar) leads to vasodilation of
arteries (red) and veins (blue) in healthy subjects (middle) and to a lesser extent in subjects with vascular dysregulation (right). The green curves
indicate the normal range. (Modified from [83], with permission).
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5.7 PVD and activation of astrocytes
Glial cell activation is a typical response to injuries of the
central nervous system including the retina. The activation
of glial cells, well demonstrated by increased glial fibrillary
acidic protein staining, has been described in the
retina in response to light damage or mechanical
stress and also to hypoxia. Retinal astrocytes and
Mueller cells also become activated in glaucoma. This
includes a change of both the function and the
morphology of these cells (Figure 24).
We have first described the clinical correlate of
astrocytes activation in the retina [215]. Activated
astrocytes change not only gene expression but also
their morphology, leading to an increased backscatter
[83]. Therefore, glinting spots can be recognised in
red-free photos or by time domain optical coherence
tomography [217]. Interestingly, activated astrocytes
can be particularly observed in glaucoma patients
with PVD [216].
5.8 PVD and autoregulation
Autoregulation describes the capacity to keep BF in an
organ within a certain range independently of perfusion
pressure. This is also the case for the eye, particularly
for the retina, slightly less for the ONH and only limited
for the choroid. A disturbed autoregulation has been
described both for healthy PVD subjects [206] and
for glaucoma patients with progressive disease [202].
The main impact of such a deficient autoregulation is
unstable oxygen supply with the consequences of
oxidative stress [204]. The dysfunctional autoregulation in
PVD subjects is the major link between PVD and
glaucoma [28].
5.9 PVD and the relation between peripheral and ocular
circulation
ONH BF was correlated to both finger BF and finger
temperature in PVD subjects but not in others [218].
This can be explained by deficient autoregulation
allowing systemic factors such as perfusion pressure to
dominate. The situation is different in the choroid,
which is less autoregulated and highly innervated. Here,
the BF was higher in patients with PVD, probably to
keep the temperature at the back of the eye constant
despite a reduced BF in the peripheral environment
[219]. Corneal temperature in an unselected population
correlates with finger temperature [44]. Interestingly,
OBF and finger BF changes induced by cold provocation
were correlated in glaucoma patients but not in others
[220]. Additionally, retrobulbar BF in glaucoma patients
is also correlated with ONH BF [221].
5.10 PVD and retinal venous pressure
Retinal venous pressure (RVP) was once assumed to be
more or less equal to IOP [222], except in patients with
increased intracranial pressure [223]. After ophthalmo-
dynamometry was introduced to measure RVP, this
assumption could no longer be made [224]. RVP is
increased [15], and spontaneous venous pulsations occur
less often in glaucoma, especially in NTG patients than
in healthy controls [225]. RVP is also increased in other
conditions such as diabetic retinopathy or in the fellow
eye of patients with retinal vein occlusion. In PVD
subjects, RVP can be normal (equal to IOP); most often,
however, it is slightly or sometimes even markedly
increased.
5.11 PVD and optic disc haemorrhages
Optic disc haemorrhages (ODH) in the context of
glaucoma were first described more than 100 years
ago by Bjerrum in 1889, but studied in detail much
later [226,227]. ODH are associated with morphological
and functional progression of disease [228-230]. Interest-
ingly, the presence of ODH is strongly associated with nail
bed haemorrhages [231], indicating systemic factors
involved in the pathogenesis of ODH. The fact that ODH
occur more often in NTG [232] than in HTG patients and
that they often precede damage and occur more often in
females than in males provoked the question of a potential
Figure 24 Glial cell activation. (Top) Activation of glial cells in the
retina. Astrocytes connecting vessels with neurons (left) and irregular
pattern of activated astrocytes (right). (Middle and bottom) Activated
astrocytes increase light scattering, visible in red-free light (right), but
not visible in colour photos (left). (From [214] (top), [215] (middle)
and [216] (bottom), with permission).
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relationship between ODH and PVD. Indeed, ODH
also occur in PVD subjects without glaucoma [233].
Furthermore, ODH occur in the contra-lateral eye of
patients with retinal vein occlusion. We hypothesise
that ODH are not a consequence of a disrupted vessel
but rather of a dysfunctional blood-retinal barrier [26]
(Figure 25). ET-1 seems to be involved not only in the
pathogenesis of ODH but also in the pathogenesis of
the increase of retinal venous pressure and retinal
vein occlusion [84].
6 PVD and ophthalmic diseases
6.1 PVD and glaucoma
The pathogenesis of glaucomatous optic neuropathy
and particularly the role of OBF has been discussed
controversially [234] since the first description of
optic nerve excavation by von Graefe in the nineteenth
century. In addition to an increased IOP, the main risk
factors for glaucomatous damage are IOP fluctuations
[235,236], low BP [237,238], reduced perfusion pressure
[239] and fluctuation of perfusion pressure [240]. While it
was difficult to measure OBF in the past, the present
methods clearly reveal that OBF is reduced in glaucoma
patients, particularly if the damage is progressing despite a
normal IOP [241,242]. The reduction of OBF was often
interpreted as being only secondary to the glaucomatous
damage. This assumption was also supported by the
fact that there is only a weak relationship between
glaucomatous optic neuropathy (GON) and atherosclerosis.
Today, we know that a reduction in OBF predicts future
GON progression [243-245]. Furthermore, vascular dys-
function in glaucoma is not limited to the eyes [246]. These
facts argue in favour of a primary component of BF reduc-
tion in glaucoma. In addition, it has become evident that
OBF regulation is more important than the OBF at baseline
condition and that fluctuations in OBF are particularly
damaging [4,234]. Indeed, glaucoma patients react with an
altered OBF response when challenged by changes in
perfusion pressure [202], hypercapnia [247,248], hyperoxia,
flicker light stimulation [12] or cold provocation [220,249].
These patients also have altered vasoreactivity to ET-1
[250] and an imbalance between the vasoconstrictor ET-1
and vasodilator NO in both plasma and aqueous humour
[39,251]. The prevalence of silent myocardial ischaemic was
also higher [160,161].
But what exactly is the cause of vascular dysfunction
in glaucoma, and how does this contribute to damage?
We postulated that PVD is the major cause of vascular
dysfunction and formulated a concept of the pathogenesis
of GON (Figure 26).
While hypoxia per se may lead to some optic nerve
atrophy, it is the instability of the oxygen supply, leading
to oxidative stress, that contributes to glaucomatous
atrophy [252]. Oxygen supply fluctuates if either the
oxygen saturation of the blood fluctuates (e.g. in patients
with severe sleep apnoea) or the OBF is unstable. OBF is
unstable if either IOP fluctuates above or BP fluctuates
below the capacity of autoregulation. However, even
normal IOP and normal BP fluctuation lead to OBF
fluctuation if the autoregulation itself is disturbed. This
explains why PVD is a major risk factor for GON [3].
PVD is associated with (a) low BP, (b) increased retinal
venous pressure and (c) disturbed autoregulation.
Although these three conditions are interrelated [150],
each can also contribute to the damage independently
[253]. Figure 27 shows examples of optic nerve heads of
(a) a normal healthy subject, (b) a healthy PVD subject,
(c) an HTG patient and (d) an NTG patient. We abstain
from a detailed description of the role of OBF in glau-
coma in this review. For readers with interest in this
field, we refer to the following literature: We
summarised the role of vasospasm [1], systemic diseases
[122], OBF [4] and autoregulation [204] in the pathogen-
esis of GON and presented our pathogenetic concept
Figure 25 Pathogenesis of optic disc splinter haemorrhages.
Under normal conditions, the vessels in and around the optic nerve
head are watertight (top). If the barrier is opened at the level of the
endothelial cells (e.g. by ET-1), small molecules such as water and
fluorescein can leak out (middle). If at the same time the basal
membrane in the same area is also weakened (e.g. by MMP-9),
erythrocytes can also escape (bottom). (Modified from [26],
with permission).
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[254]. In a recent review, we further summarised the rela-
tionship between OBF and cardiovascular diseases
[163]. The vascular aspects are also included in our
glaucoma book [57]. Finally, the relationship between
BF and glaucoma was described in detail in a pock-
etbook [255].
6.2 PVD and other eye diseases
6.2.1 Retinal arterial occlusion
Retinal arterial occlusions normally occur in elderly
patients with risk factors for atherosclerosis. Rarely, such
occlusions occur also in young subjects without any
signs of atherosclerosis [256]. It is sometimes explained by
factors such as hyperhomocysteinemia [257], although the
causal relationship remains unclear. Occlusions rarely
occur during a migraine attack [258]. Most of these young
and otherwise healthy patients with arterial occlusion suf-
fer from PVD [1] and have slightly increased plasma level
of ET-1 [81]; often, the occlusion is reversible [259].
6.2.2 Retinal vein occlusion
Retinal vein occlusion (RVO) occurs most often in
elderly patients with vascular risk factors such as
systemic hypertension and in patients with glaucoma.
RVO, however, can sometimes occur in relatively young
subjects without risk factors for atherosclerosis and
without glaucoma. Most of these patients suffer from
PVD [260]. We made the clinical observation that RVO
in such PVD subjects most often occurred after a major
stress episode. An association with both a cilioretinal
artery occlusion [261] and with retinal arterial vasospasm
has been described [262]. As in the older and more
classical RVO patients [82], these young subjects also have
increased ET-1 plasma levels [81]. We know from experi-
mental studies that ET-1 injection in the vitreous body
leads to transient complete obstruction of retinal vessels
[85]. We hypothesised that RVO may primarily be caused
by a local ET-1-induced constriction of the vein, either at
Figure 26 There are two major risk factors for GON: PVD and IOP. PVD decreases perfusion pressure by lowering blood pressure and by
increasing retinal venous pressure. Increased IOP also reduces perfusion pressure and activates the astrocytes. PVD also leads to disturbed
autoregulation and therefore to an unstable OBF. This in turn leads to oxidative stress. Oxidative stress together with activated astrocytes leads to
the damaging peroxynitrite and cell death.
Figure 27 Typical examples of optic nerve heads. Taken from (A)
a healthy subject, (B) a healthy subject with PVD, (C) an HTG patient
(vessels are pushed towards the nasal quarter of the excavation) and
(D) an NTG patient with PVD (vessels are not pushed to the nasal
side, and the remaining neuroretinal rim is slightly pale). The rings
highlight the local manifestations of vascular dysregulations.
Flammer et al. The EPMA Journal 2013, 4:14 Page 21 of 33
http://www.epmajournal.com/content/4/1/14
the arterio-venous crossing in the retina or at the
level of the lamina cribrosa. ET-1 diffuses either from
the fenestrated capillaries of the choroid, from
diseased arteries or from hypoxic retinal tissue to the
vein [84] (Figure 28).
In contrast to what is often assumed, veins are not
passive tubes but respond very sensitively to vasoactive
hormones. Impaired generalised endothelial function in
patients with RVO [263] has been reported, and this is
compatible both with atherosclerosis of older patients
and with PVD of younger subjects.
6.2.3 Anterior ischaemic optic neuropathy
As with all arterial occlusions, atherosclerosis and its
risk factors also play a major role for anterior ischaemic
optic neuropathy (AION). Like retinal arterial occlusion
and RVO, AION can occur in young subjects without
any risk factors for atherosclerosis as well. We made the
observations that the vast majority of these patients are
PVD subjects and that the occlusions occur in most
cases after major psychological stress [264,265] or,
alternatively, are drug induced [266]. AION, however,
can also be observed secondarily to other diseases (see
‘Secondary vascular dysregulation’) such as autoimmune
diseases [267].
6.2.4 Susac syndrome
The syndrome was named after J.O. Susac, who first
described it in 1979 [268]. It is characterised by the clinical
triad of encephalopathy, branch retinal artery occlusion
[269] and sensorineural hearing loss. Like PVD, it mainly
occurs in young women. It is generally assumed that an
autoimmune process leads to damage and inflammation-
related occlusion of the microvessels in the brain, retina
and inner ear. Indeed, anti-endothelial cell antibodies could
be detected in some patients [270]. It remains, however,
unclear whether this is a primary or secondary event as, on
the one hand, autoimmunity can lead to ischemia and, on
the other hand, ischaemic lesions can induce autoimmun-
ity. All patients we had the opportunity to examine
suffered from the classical symptoms and signs of PVD
[271] (Figure 29). As discussed with multiple sclerosis, fur-
ther studies are necessary to sort out what came first in
these Susac patients: the dysregulation or the autoimmun-
ity (see ‘Causes of SVD’).
6.2.5 PVD and optic nerve compartment syndrome
Cerebrospinal fluid normally communicates freely through-
out all CSF compartments. CSF sampled during lumbar
puncture is therefore considered to be representative for all
CSF compartments in terms of pressure and composition.
However, in optic nerve compartment syndrome,
there is proven segregation of CSF between the intra-
cranial subarachnoid space and the subarachnoid
space surrounding the optic nerve [272]. This compartment
[273] is characterised by measurable differences of fluid
composition [274], comparable to the composition of the
subretinal fluid [275], reduced CSF exchange [273]
(Figure 30) and extension of the optic nerve sheath diam-
eter due to increased pressure [276,277]. These patients are
often referred because of visual field defects. The visual
field can be concentric constricted or more glaucoma-like,
while visual acuity is often but not always reduced. The
ONH is mostly more or less atrophic, sometimes
glaucoma-like excavated [278] as we see in NTG [279] and
rarely swollen [280]. The retinal venous pressure is nearly
always increased.
The increase of CSF pressure leads to proliferation of
meningothelial cells [281,282]. These cells participate in
immunological processes in the CSF [283]. The change in
the concentration of CSF proteins such as lipocalin-like
prostaglandin-D- synthase could harm the neurons [284].
The pathogenesis of the compartment syndrome is not
yet clear. A reduced outflow of the CSF through the
lymphatic vessels may contribute [285-287]. It is our
clinical experience that the majority of patients with
optic nerve compartment syndrome are PVD patients.
We have also observed that a treatment of PVD very
often reduces the extension of the optic nerve sheath
diameter and reduces retinal venous pressure in patients
Figure 28 Pathogenesis of retinal vein occlusion. At the lamina cribrosa, the central retinal artery and central retinal vein are topographically
very close and share a common adventitia (middle). This enables a molecular crosstalk between the two vessels (right). ET-1 (blue), for example,
can diffuse from the ailing artery as well as from the adjacent hypoxic tissue to the very sensitive vein, leading to venous constriction. (Modified
from [84], with kind permission from Springer Science + Business Media B.V.).
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that had recently developed a compartment syndrome.
In more advanced cases, steroids sometimes help,
whereas in very advanced cases, only optic nerve sheath
fenestration is helpful. We assume that the unstable oxygen
supply due to PVD may lead to chronic inflammation via
oxidative stress. This in turn could induce swelling and
proliferation of the arachnoid trabeculae leading to a
kind of valve allowing CSF to enter in the optic nerve
compartment but hindering the backflow.
6.2.6 Central serous chorioretinopathy
Central serous chorioretinopathy is a common disorder
characterised by accumulation of serous fluid under the
neurosensory retina secondary to a localised defect of
the outer blood-retinal barrier. The pathogenesis is
controversial. We hypothesised that local vascular
dysregulation in the choroidal BF plays a major role [288].
This assumption is based on the following observations: (a)
indocyanine green angiography done during the acute
phase revealed delayed filling and venous congestion in the
corresponding area of the choroid most likely induced
by venous constriction (Figure 31), (b) it is most
often preceded by a major psychological stress and
occurs more often in subjects with so-called type-A
behaviour, and (c) it can be provoked by intravenous in-
jection of epinephrine. The resulting hypoxia in the area
of the corresponding lobulus may then secondarily break
down the outer blood-retinal barrier.
We further observed that these patients were mostly
PVD subjects and had increased ET-1 plasma level
during the acute phase; in addition, they often showed
increased retinal venous pressure. Interestingly, it occurs
particularly often in young men. Male hormones
most likely play a role. Once, a 45-year-old woman
with a history of metamorphopsia was referred to
our institution, and we diagnosed a classical central
serous chorioretinopathy in a PVD subject under
major professional stress. We told her that she was
suffering from a disease we most often see in young
men. On her second visit, she mentioned that she
had been taking 40 mg of oral testosterone a day for the
previous 2 months for better professional performance.
Plasma testosterone level was markedly increased. We
stopped testosterone treatment, and she recovered quickly
and remained free of symptoms the following years [289].
6.2.7 Leber hereditary optic neuropathy
Leber hereditary optic neuropathy (LHON) is a maternally
inherited disorder resulting from point mutations in mito-
chondrial DNA (mtDNA) [290]. Ophthalmologic findings
in LHON patients are variable, but classical LHON cases
exhibit vascular tortuosity of the central retinal vessels,
swelling of the retinal nerve fibre layer, a circumpapillary
Figure 30 Cisternography of a patient with optic nerve
compartment syndrome. Normal contrast-loaded cerebrospinal
fluid in the pituitary cistern is indicated by a star. Stopping of the
contrast-loaded cerebrospinal fluid in the posterior portion of the
intraorbital subarachnoid space in both optic nerves is indicated by
arrows (Courtesy of Killer HE).
Figure 29 Susac syndrome in a patient with severe PVD. (Left) MRI of the pons with a hyperintensive lesion. (Middle) Localised retinal
infarction. (Right) Corresponding visual field defects. (From [271], with permission).
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telangiectatic microangiopathy and a cecocentral scotoma
with variable preservation of peripheral vision. The disease
finally leads to optic disc atrophy. Despite a clear genetic
background, other factors play a role in manifestation and
progression for the following reasons: (a) not all patients
harbouring a pathogenic LHON mtDNA mutation develop
the disease, (b) patients live free of symptoms many years
before the onset of the disease, and (c) only a few organs
and particularly the visual system get sick. It is likely that
internal or external factors additionally damaging mito-
chondria are contributing factors, such as smoking,
excessive alcohol, light exposure [291] and age. We made
the clinical observation that the majority of patients we
saw with LOHN were PVD subjects. There are many
possible interpretations of this: (a) it could be referral bias,
(b) subjects with mitochondrial mutations have higher risk
for PVD, or (c) PVD subjects have unstable OBF
leading to oxidative damage of the mitochondria and
thereby increasing the probability that mitochondria with
pre-existing mutations decompensate. The relationship
between LOHN and NTG is unclear, but the majority of
NTG patients have no mtDNA mutations [292]. However,
we saw a young man with PVD and acute unilateral LOHN
in his right eye, who developed NTG in his unaffected left
eye over the following 10 years.
6.2.8 Retinitis pigmentosa
Retinitis pigmentosa (RP) encompasses a large group of
hereditary diseases of the posterior segment of the eye
characterised by degeneration, atrophy and, finally, loss of
photoreceptors and retinal pigment epithelium, leading to
progressive visual loss. Even though the disease has a
genetic background, we assume that additional factors
influence the manifestation of the disease. One potential
modifying factor is disturbed OBF. Indeed, reduced OBF in
RP patients has been described. BF is more or less always
reduced in atrophic tissue, secondary to a decreased
demand for supply. However, there are indications of an
additional primary component mainly caused by PVD. We
refer to a recent review [293].
7 Therapy
Although vascular dysregulation is frequent, often
cumbersome and sometimes damaging, little research
has been conducted to develop treatments. The
present therapeutic armamentarium therefore is very
limited and mainly based on clinical experience. The
majority of PVD subjects do not need any treatment
because they are healthy. Treatment should be
considered if these subjects are bothered by signs and
symptoms or if they show PVD-related disease like
progressive NTG.
7.1 Lifestyle
To some extent, PVD subjects can reduce their
symptoms by lifestyle modification. They should avoid,
as far as this is possible, major emotional stress. In
glaucoma patients with PVD, we often observed very fast
progression of visual field defects during a major stress
event, for example, in the context of a divorce. It has
recently been shown that women who commonly
suppress anger experience more thermal discomfort
from cold extremities and have prolonged sleep onset
latency [47]. Furthermore, PVD subjects should avoid
extensive cold. We observed two PVD subjects that
acquired sudden and irreversible bundle-shaped visual
field defects during skiing. One woman with PVD
repeatedly lost consciousness after jumping in cold water.
PVD subjects are mostly slim, but we recommend that
PVD subjects keep their BMI not too low and avoid major
fasting periods. PVD subjects should not exaggerate with
sport. We observed a fast progressive NTG in a young
man bicycling every day for several hundred kilometres in
a mountainous area. After he stopped doing this, his NTG
stabilised. Daily mild physical activity, however, is
helpful. PVD subjects should be careful climbing high
mountains too quickly. Altitude sickness seems to be
stronger in these subjects. We observed a young
female ophthalmologist with marked PVD symptoms
who lost her fingers and toes at high altitude. We
further recommend avoiding strong light and wearing
Figure 31 Angiography of a 46-year-old female subject with recurrent central serous chorioretinopathy. (Left) Disorder of the retinal
pigment epithelium with leakage. (Middle) Slight congestion in the early capillary filling phase in indocyanine green angiography. (Right)
Congestion of the draining veins clearly visible in the venous filling phase. (From [288], with permission).
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sunglasses. Similar to an unstable oxygen supply, light
induces oxidative stress and damages the mitochondria
[294-296]. We examined a gastroenterologist who had
performed more than 22,000 endoscopies with his
preferred left eye (this was before the advent of video
monitors). In this left eye, he acquired colour vision
deficiency, reduced contrast sensitivity and inhomogeneity
of the pigment in the macular area, whereas the other eye
remained normal [297].
7.2 Nutrition
We recommend a diet containing fruits and vegetables,
particularly if they are rich in antioxidants such as
anthocyanosides or flavonoids. Black currant anthocyanins
have been shown to normalise abnormal levels of serum
concentrations of ET-1 in patients with glaucoma [298].
Food rich in flavanols, particularly cocoa, may improve
endothelial function in general [299]. Food rich in
omega-3 fatty acids improves vascular regulation
[300]. We also recommend green tea [301]. If BP is
very low, salt intake should be increased [302]. For a more
detailed description of our recommendation on nutrition,
we refer to the book Ocular Blood Flow and Glaucomatous
Optic Neuropathy [255].
7.3 Magnesium
Magnesium is cheap and has few side effects. In ex vivo
studies, it reduces the vasoconstrictive effect of ET-1
(Figure 32) [303] and potentially has a positive effect on
visual fields [304].
7.4 Calcium channel blockers
CCBs are the classical anti-vasospastic drugs at present
[197,305]. They reduce the effect of ET-1 [306,307] and
improve visual fields of PVD patients [265]. It is not
clear yet which of the CCBs is best and whether water-
soluble or fat-soluble CCBs should be used. We use
water-soluble CCBs like nifedipine for glaucoma and
fat-soluble CCBs like nimodipine for retinal diseases.
To reach the ONH of glaucoma patients, the drugs
do not need to cross the blood–brain barrier. It is im-
portant to use very low doses [60] for the following reasons:
(1) already low doses show efficient anti-vasospastic effects,
(2) the drug sensitivity of PVD subjects is increased, and (3)
in most cases, we do not want to further decrease BP. Ni-
fedipine improves capillary BF in PVD subjects [308]. In a
placebo-controlled 3-year study, nilvadipine slowed the vis-
ual field progression, maintained the optic disc rim and in-
creased choroidal circulation in patients with NTG [309].
The better visual field preservation effect of betaxolol over
timolol is most likely also due to the calcium antagonising
side effect of betaxolol [310]. Topical flunarizine reduces
IOP and protects the retina against ischaemic-excitotoxicity
[311]. The use of CCBs in glaucoma has recently been
reviewed [198,312].
7.5 Endothelin antagonists
Bosentan, a dual endothelin receptor antagonist,
reduces coronary vasospasm [313], cerebral vaso-
spasm [314] and pulmonary vasoconstriction [315]
and increases OBF in patients with glaucoma [316].
Avosentan, an ET(A)-endothelin receptor antagonist,
relaxes ciliary arteries [317]. Sulfisoxazole, another
ET receptor antagonist, protects retinal neurons from
the insult of ischaemic/reperfusion [318]. Nevertheless, a
routine use of ET blockers at present is not or not
yet recommended for treatment of PVD due to potential
side effects.
7.6 Fludrocortisone
The rare PVD patients who have extremely low BP, not
responding to salt intake, we treat with the mineralocor-
ticoid fludrocortisone [319] at very low doses (0.1 mg
twice a week). Even when only a slight BP increase is
achieved, haemodynamic parameters are improved
[320].
7.7 Carboanhydrase inhibitors
In the early 1970s, Paterson [321] and Heilmann [322]
described visual field reversibility in glaucoma patients
after treatment with acetazolamide. We confirmed these
findings [323] and postulated a relationship with an
improvement of OBF. This effect occurred particularly
in young female subjects [199]. Today, we know that
both the systemically applied acetazolamide as well as
the locally applied dorzolamide improve OBF [324].
Figure 32 Similar relaxing effect of increasing MgSO4 and
MgCl2 concentrations added to ET-1 precontracted ciliary
arteries. (Modified from [303], with permission).
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7.8 Ginkgo biloba
Oxidative stress occurs particularly in the mitochondria,
where it damages the inner membrane. While vitamins
do not reach this area, G. biloba polyphenols may
protect the mitochondria. For more details, we refer
to a recent review [325].
7.9 Other drugs
A female patient with advanced NTG and PVD took
sildenafil for better vision. Indeed, sildenafil increases BF in
the choroid [326], and we observed dilatation of retinal
arteries and veins in healthy subjects after intake [327].
Whether a long-term treatment with a phosphodiesterase-5
inhibitor is helpful or counterproductive in PVD subjects is
unclear as of now.
In ex vivo studies, dipyridamole dilated ciliary arteries,
and pre-incubation with dipyridamole reduced contractions
to ET-1 [328]. In clinical short-term studies, dipyridamole
increased BF velocities in the extraocular vessels [329].
However, long-term studies are not available so far.
8 Conclusions
Although PVD syndrome is quite prevalent and
mostly benign, it can be accompanied by bothering
symptoms and may contribute to the occurrence and
progression of potentially serious diseases such as
NTG. Despite the emphasised importance, we are
still in the infant stage of the research in this field.
Taking into consideration the prevalence of PVD in
the population, the authors strongly recommend the
following steps to be undertaken in order to effectively
promote the field:
 While in the past nailfold capillaroscopy was
considered to be the gold standard for the diagnosis
of PVD, we may need to redefine it. The proposed
minimally invasive biomarker panels besides imaging
by nailfold capillary microscopy with cold
provocation are the dynamic retinal vessel imaging
with flicker light stimulation or the pathology-
specific molecular profiles in circulating leukocytes.
 The phenomenology of the syndrome needs to be
further qualitatively and quantitatively characterised
to enable early diagnosis, pathology prediction and
targeted prevention in groups at risk. This task is of
particular value from the viewpoint of ethics and
positive economy of medical services.
 The underlying pathophysiology should be studied
in more detail. Concretely, the role of the autonomic
nervous system, vascular endothelial cells or even
that of the mitochondria needs to be clarified in
order to develop highly sensitive diagnostic tools
and to promote therapy approaches tailored to
the person.
 The functional link between vascular dysregulation
and the spectrum of related and downstream
diseases needs to be established.
 The present treatment is of limited value and not
yet based on well-controlled studies. Once the role
of the syndrome is established and accepted by the
scientific community, innovative diagnostic tools
might be created and the pharmaceutical industry
can get motivated to develop novel drug targets and
more efficient treatment approaches.
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